A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke

International Journal of Stroke

Volumn 9, Issue 3, 2014, Pages 381-386

  Hess, David C ^a   Sila, Cathy A ^b   Furlan, Anthony J ^b   Wechsler, Larry R ^c   Switzer, Jeffrey A ^a   Mays, Robert W ^d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d ATHERSYS INC   (United States)

Author keywords

Clinical trial; Ischemic stroke; Multipotent stem cell; Spleen; Stem cell

Indexed keywords

PLACEBO;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BARTHEL INDEX; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; SPLEEN SIZE; YOUNG ADULT;

CLINICAL TRIAL; ISCHEMIC STROKE; MULTIPOTENT STEM CELL; SPLEEN; STEM CELL;

ADOLESCENT; ADULT; AGED; BRAIN ISCHEMIA; CELL- AND TISSUE-BASED THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); STROKE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84896316934     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12065     Document Type: Article

References (34)

1. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009; 40:510-515.
2. Albers GW, Goldstein LB, Hess DC etal. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke 2011; 42:2645-2650.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
4. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40:2945-2948.
5. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
6. Hess DC, Hill WD. Cell therapy for ischaemic stroke. Cell Prolif 2011; 44(Suppl 1):1-8.
7. Lee RH, Pulin AA, Seo MJ etal. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5:54-63.
8. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab 2006; 26:654-665.
9. Offner H, Subramanian S, Parker SM etal. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol 2006; 176:6523-6531.
10. Schwarting S, Litwak S, Hao W, Bahr M, Weise J, Neumann H. Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke 2008; 39:2867-2875.
11. Vendrame M, Gemma C, Pennypacker KR etal. Cord blood rescues stroke-induced changes in splenocyte phenotype and function. Exp Neurol 2006; 199:191-200.
12. Shen LH, Li Y, Chen J etal. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab 2007; 27:6-13.
13. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815-1822.
14. Beyth S, Borovsky Z, Mevorach D etal. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105:2214-2219.
15. Jiang Y, Vaessen B, Lenvik T, Blackstad M, Reyes M, Verfaillie CM. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 2002; 30:896-904.
16. Jiang Y, Henderson D, Blackstad M, Chen A, Miller RF, Verfaillie CM. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proc Natl Acad Sci U S A 2003; 100(Suppl 1):11854-11860.
17. Jiang Y, Jahagirdar BN, Reinhardt RL etal. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418:41-49.
18. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002; 174:11-20.
19. Van Bokkelen G. Company profile: Athersys. Regen Med 2011; 6:39-43.
20. Yasuhara T, Matsukawa N, Yu G etal. Transplantation of cryopreserved human bone marrow-derived multipotent adult progenitor cells for neonatal hypoxic-ischemic injury: targeting the hippocampus. Rev Neurosci 2006; 17:215-225.
21. Yasuhara T, Matsukawa N, Yu G etal. Behavioral and histological characterization of intrahippocampal grafts of human bone marrow-derived multipotent progenitor cells in neonatal rats with hypoxic-ischemic injury. Cell Transplant 2006; 15:231-238.
22. Mays RW, Borlongan CV, Yasuhara T etal. Development of an allogeneic adherent stem cell therapy for treatment of ischemic stroke. J Exp Stroke Transl Med 2010; 3:34-46.
23. Busch SA, Hamilton JA, Horn KP etal. Multipotent adult progenitor cells prevent macrophage-mediated axonal dieback and promote regrowth after spinal cord injury. J Neurosci 2011; 31:944-953.
24. Walker PA, Shah SK, Jimenez F etal. Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: preserving the blood brain barrier via an interaction with splenocytes. Exp Neurol 2010; 225:341-352.
25. Kovacsovics-Bankowski M, Streeter PR, Mauch KA etal. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol 2009; 255:55-60.
26. Mays RW, van't Hof W, Ting AE, Perry R, Deans R. Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin Biol Ther 2007; 7:173-184.
27. Ting AE, Mays RW, Frey MR, Hof WV, Medicetty S, Deans R. Therapeutic pathways of adult stem cell repair. Crit Rev Oncol Hematol 2008; 65:81-93.
28. Aranguren XL, McCue JD, Hendrickx B etal. Multipotent adult progenitor cells sustain function of ischemic limbs in mice. J Clin Invest 2008; 118:505-514.
29. Sohni A, Verfaillie CM. Multipotent adult progenitor cells. Best Pract Res Clin Haematol 2011; 24:3-11.
30. Van't Hof W, Mal N, Huang Y etal. Direct delivery of syngeneic and allogeneic large-scale expanded multipotent adult progenitor cells improves cardiac function after myocardial infarct. Cytotherapy 2007; 9:477-487.
31. Penn MS, Ellis S, Gandhi S etal. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res 2012; 110:304-311.
32. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57:874-882.
33. Wang X, Takagawa J, Lam VC etal. Donor myocardial infarction impairs the therapeutic potential of bone marrow cells by an interleukin-1-mediated inflammatory response. Sci Transl Med 2011; 3:100ra90.
34. Cheung K, Kaufmann P. Efficiency perspectives on adaptive designs in stroke clinical trials. Stroke 2011; 42:2990-2994.